Kane Biotech ((TSE:KNE)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Kane Biotech Inc., in collaboration with the University of Miami, is launching a clinical study titled ‘Split-face Efficacy and Tolerability of DispersinB Acne Cleanser in the Treatment of Mild to Moderate Acne Vulgaris.’ The study aims to evaluate the effectiveness and tolerability of DispersinB Acne Cleanser in treating facial acne. The primary objectives include assessing the percentage of subjects rated as ‘Clear’ or ‘Almost Clear’ and changes in lesion count after 12 weeks of treatment.
The intervention being tested is the DispersinB Acne Cleanser, a topical gel designed to treat acne. It will be compared against a standard 4% Benzoyl Peroxide facial wash in a split-face study, where each participant will use both treatments on different halves of their face.
This interventional study follows a single-group model with no masking, focusing on treatment as its primary purpose. Participants will be randomized to apply the DispersinB Acne Cleanser to one side of their face for 12 weeks, allowing for direct intra-individual comparison.
The study is set to begin recruitment on December 5, 2024, with an estimated completion date in 2025. The most recent update was submitted on May 8, 2025, indicating ongoing preparations for the trial.
For investors, this study could signal potential growth for Kane Biotech if the results demonstrate significant efficacy and tolerability. Positive outcomes might enhance the company’s market position in the acne treatment industry, potentially influencing stock performance. Competitors in the acne treatment market will likely monitor these developments closely.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.